

# Pharmacy and Therapeutics Committee

## Meeting Minutes

Thursday, March 21, 2019  
7:00 a.m. to 8:45 a.m.  
Cannon Health Building  
Room 125

**Committee Members Present:**

McKay Robinson, PharmD  
Clayton Grace, RPh  
Cole Sloan, PharmD  
Michelle Hofmann, MD

Bryan Larson, PharmD  
Clinton Sheffield, MD  
Elizabeth Young, PharmD  
Susan Siegfried, MD

**Committee Members Excused:**

Christopher Valentine, MD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Jennifer Strohecker, PharmD, Pharmacy  
Director  
Joe Busby, RPh, MBA

Merelynn Berrett, RN  
Heather Santacruz, RN

**University of Utah Drug Regimen Review Center Staff Presenter:**

Valerie Gonzales, PharmD

Lauren Heath, PharmD

**Other Individuals Present:**

Ryan Flugge, Novo Nordisk  
Lori Howarth, Bayer  
Elena Martinez, U of U

Michele Puyear, Gilead  
Tony Patterson, DOH  
Rob Booth, Allergan

Meeting conducted by: McKay Robinson

---

1. **Welcome & Housekeeping:** McKay Robinson opened the meeting and announced a quorum
  - a. McKay Robinson announced two new members of the P&T Committee; Christopher Valentine, and Michelle Hofmann.
2. **Review and Approval of November Minutes:** McKay Robinson made a motion to approve the minutes from November. Cole Sloan seconded the motion. All in favor, motion passed. Clayton Grace, Elizabeth Young, and Clinton Sheffield were not present for this vote.
3. **Annual Training:** Tony Patterson provided annual training on Utah Code – Title 52 – Chapter 04 – Open Public Meetings Act.
4. **Drug Utilization Review (DUR) Board update:** Over the last three months, the DUR has discussed CGRP Inhibitors, atopic dermatitis and moderate to severe psoriasis, and the anti-epileptics Epidiolex and Diacomit. Two new members have

# Pharmacy and Therapeutics Committee

## Meeting Minutes

joined the DUR Board; the board still has a vacancy for a dentist. Next month, the University of Utah Drug Regimen Review Center (DRRC) will be presenting the retroDUR work they do for Medicaid.

5. **Insulins – Rapid Acting and Basal:** (insulin aspart, insulin glulisine, insulin lispro, insulin regular, insulin degludec, insulin detemir, insulin glargine). Valerie Gonzales presented a review of rapid acting and basal insulins. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines, and Utah Medicaid utilization data.
6. **Public Comment:**
  - a. Ryan Flugge from Novo Nordisk presented information pertaining to Tresiba and Fiasp.
7. **Other State Report:** Bryan Larson reported PDL listings for insulins in other States' Medicaid programs.
8. **Committee Discussion:**
  - a. Bryan Larson made a motion that insulin degludec and insulin glargine U-300 are equally safe and efficacious to each other and that one of them be preferred on the PDL. Elizabeth Young seconded the motion. Seven in favor with Clinton Sheffield opposed. Motion passed.
  - b. Bryan Larson made a motion that for all other insulins, the status quo is maintained and that they are equally safe and efficacious within their respective groupings. McKay Robinson seconded the motion. Unanimous approval, motion passed.
9. **ACE Inhibitors/ACE Inhibitor Combinations:** (benazepril, benazepril/amlodipine, benazepril/hctz, captopril, captopril/hctz, enalapril, enalapril/hctz, fosinopril, fosinopril/hctz, lisinopril, lisinopril/hctz, moexipril, moexipril/hctz, perindopril, perindopril/amlodipine, quinapril, quinapril/hctz, ramipril, trandolapril, trandolapril/verapamil). Lauren Heath presented a review of ACE inhibitors and ACE inhibitor combinations. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines, and Utah Medicaid utilization data.
10. **Public Comment:**
  - a. No public comment.
11. **Other State Report:** Bryan Larson reported PDL listings for ACE inhibitors and ACE inhibitor combinations in other States' Medicaid programs.
12. **Committee Discussion:**
  - a. Clinton Sheffield made a motion that ACE inhibitors and ACE inhibitor combinations are equally safe and efficacious. Elizabeth Young seconded the

## Pharmacy and Therapeutics Committee

### Meeting Minutes

motion. Unanimous approval, motion passed.

- b. Michelle Hofmann made a motion that at least one liquid agent be preferred for patients less than or equal to 12 years of age. Susan Siegfried seconded the motion. Unanimous approval, motion passed.

13. **Public Meeting Adjourned:** McKay Robinson motioned to close the meeting. Cole Sloan seconded the motion. Unanimous approval, motion passed.

14. **Next meeting is scheduled for** June 20, 2019 ADHD Stimulants, Sedative Hypnotics (non-benzodiazepine, non-barbiturate).

---

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>